Clinical Trials Browser

Esophageal Squamous Cell Carcinoma

NCT06535607 2026-05-26

eVOLVE-02

Phase 2 Recruiting

257 enrolled

GastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms

NCT04389632 2026-05-11

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Phase 1 Recruiting

1,006 enrolled

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Clinical Trials

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

eVOLVE-02

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

NTNC

Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

HYPERION

KEYSTONE-002